Cephamycin resistance in clinical isolates and laboratory-derived strains of Escherichia coli, Nova Scotia, Canada

Emerging Infectious Diseases

Volumn 9, Issue 10, 2003, Pages 1254-1259

  Clarke, Brian ^a   Hiltz, Margot ^a   Musgrave, Heather ^a   Forward, Kevin R ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAMASE; CEFALOTIN; CEFOXITIN; CEPHAMYCIN; IMIPENEM; PORIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CANADA; CONTROLLED STUDY; ESCHERICHIA COLI; GENE EXPRESSION; GENE MUTATION; ISOELECTRIC FOCUSING; LABORATORY DIAGNOSIS; MOLECULAR DYNAMICS; NONHUMAN; OMPC GENE; OMPF GENE; POINT MUTATION; PROMOTER REGION; PULSED FIELD GEL ELECTROPHORESIS; STRAIN DIFFERENCE; VIRAL GENETICS;

EID: 0141643241     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0910.030093     Document Type: Article

References (22)

1. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002;46:2540-5.
2. Goldraich NP, Manfroi A. Febrile urinary tract infection: Escherichia coli susceptibility to oral antimicrobials. Pediatr Nephrol 2002;17:173-6.
3. Sahm DF, Marsilio MK, Piazz G. Antimicrobial resistance in key bloodstream bacterial isolates: electronic surveillance with the Surveillance Network Database-USA. Clin Infect Dis 1999;29:259-63.
4. Olsson O, Bergstrom S, Normark S. Identification of a novel AmpC beta-lactamase promoter in a clinical isolate of Escherichia coli. Embo J 1982;1:1411-6.
5. Caroff N, Espaze E, Berard I, Richet H, Reynaud A. Mutations in the AmpC promoter of Escherichia coli isolates resistant to oxyiminocephalosporins without extended spectrum beta-lactamase production. FEMS Microbiol Lett 1999;173:459-65.
6. Nelson EC, Elisha BG. Molecular basis of AmpC hyperproduction in clinical isolates of Escherichia coli. Antimicrob Agents Chemother 1999;43:957-9.
7. Forward KR, Willey BM, Low DE, McGeer A, Kapala MA, Kapala MM, et al. Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitals. Diagn Microbiol Infect Dis 2001;41:57-63.
8. Bauernfeind A, Chong Y, Lee K. Plasmid-encoded AmpC beta-lactamases: how far have we gone 10 years after the discovery? Yonsei Med J 1998;39:520-5.
9. Gautom RK. Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other gram-negative organisms in 1 day. J Clin Microbiol 1997;35:2977-80.
10. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-5.
11. Martinez-Flores I, Cano R, Bustamante VH, Calva E, Puente JL. The ompB operon partially determines differential expression of OmpC in Salmonella typhi and Escherichia coli. J Bacteriol 1999;181:556-62.
12. Rice LB, Bonomo RA. Genetic and biochemical mechanisms of antibacterial resistance to antimicrobial agents. In: Lorian V, editor. Antibiotics in laboratory medicine. 4th ed. Baltimore: Williams and Wilkins; 1996. p. 282.
13. Matthew M, Harris AM. Identification of beta-lactamases by analytical isoelectric focusing: correlation with bacterial taxonomy. J Gen Microbiol 1976;94:55-67.
14. Corvec SCN, Espaze E, Marraillac J, Reynaud A. Analysis of the effect of the -11 AmpC promoter mutation in clinical strains of Escherichia coli. In: Abstracts of the 41st Interscience Conference on Autimicrobial Agents and Chemotherapy. Sep 2001; Chicago, IL.
15. Rice LB, Carias LL, Hujer AM, Bonafede M, Hutton R, Hoyen C, et al. High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Chemother 2000;44:362-7.
16. Bornet C, Davin-Regli A, Bosi C, Pages JM, Bollet C. Imipenem resistance of Enterobacter aerogenes mediated by outer membrane permeability. J Clin Microbiol 2000;38:1048-52.
17. Bradford PA, Urban C, Mariano N, Projan SJ, Rahal JJ, Bush K. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC beta-lactamase, and the foss of an outer membrane protein. Antimicrob Agents Chemother 1997;41:563-9.
18. Stapleton PD, Shannon KP, French GL. Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 beta-lactamase production and loss of an outer membrane protein. Antimicrob Agents Chemother 1999;43:1206-10.
19. Martinez-Martinez L, Hernandez-Alles S, Alberti S, Tomas JM, Benedi VJ, Jacoby GA. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum-cephalosporins. Antimicrob Agents Chemother 1996;40:342-8.
20. Lan CY, Igo MM. Differential expression of the OmpF and OmpC porin proteins in Escherichia coli K-12 depends upon the level of active OmpR. J Bacteriol 1998;180:171-4.
21. Simonet V, Mallea M, Pages J-M. Substitutions in the eyelet region disrupt cefepime diffusion through the Escherichia coli OmpF channel. Antimicrob Agents Chemother 2000;44:311-5.
22. Jeanteur D, Schirmer T, Fourel D, Simonet V, Rummel G, Widmer C, et al. Structural and functional alterations of a colicin-resistant mutant of OmpF porin from Escherichia coli. Proc Natl Acad Sci U S A 1994;91:10675-9.